Abstract 12P
Background
Mobile health apps are increasingly gaining attention as opportunities to obtain patient-generated health data without asking for self-report or visiting hospital. Since there are few studies regarding the mobile-based activity trackers in breast cancer patients, we decided to evaluate the feasibility of a mobile walking app and a smart band as a tool for collecting physical activity of breast cancer patients.
Methods
Between June 2017 and March 2018, patients who received surgery for breast cancer at Asan Medical Center were enrolled and asked to access two mobile apps on a weekly basis during a six-month period to automatically record their daily physical activity. Compliance rates of the daily collection via a smartphone walking app and a wearable smart band were compared in a within-subject manner. Longitudinal daily collection rates were calculated to examine a drop-out pattern. Finally, we examined factors associated with the compliance of daily collections using multivariate linear regression analysis.
Results
A total of 160 participants were analyzed, and they are asked to follow an instruction to access the apps at least once a week via their smartphones. Despite the fact that both smartphone app and the smart band showed more than 50% of compliance rate during the six-month follow-up period, smartphone walking app demonstrated higher overall compliance rate (88%) than a smart band (52%). The median value of individual compliance rate is 91% for the walking app and 55% for a smart band. Women having other diseases, an anti-hormonal therapy or a targeted therapy show a higher compliance rate to smartphone walking app, and young women show a higher rate to the app than older women. However, there was no association between any of the patient characteristics and a compliance rate to the smart band.
Conclusions
Smartphone apps or smart bands are feasible tools to collect daily physical activity data for in breast cancer survivors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yungil Shin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract